Saturday 17 October 2026 Export CATX’s income statement to Excel — free account

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 72.1%, EPS grew 24.1%, free cash flow fell 66.1% and total debt fell 3.57%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.17 0.17 −7.26%

Follow CATX

Alert me

Market cap: $267.1M
P/E: 0.0×
Fwd P/E: −2.7×
Dividend yield: —
F-score: 3/9
Altman Z: −0.59
Beneish M: 0.59
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.04

Total sells 1.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	2	3	—

Insider Ownership 21.23%

Capital & Financial Ratios $m

Market Cap 267.12

Revenue 0.41

Net Income (116.43)

Free Cash Flow (121.19)

Net Debt (235.34)

Current Ratio 6.61

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.74)

P/S ratio 640.13

P/B ratio 0.81

Past 5Y EPS Growth —

This Y EPS Growth 30.62%

Next Y EPS Growth (5.31%)

Next Y revenue growth (62.22%)

Next 5Y EPS Growth 11.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 95.21%

10-year low 10-year high

P/B against its own 10 years 13.90%

10-year low 10-year high

EV/Sales against its own 10 years 75.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	227	145	237
Receivables	1	0	0	0
Inventory	—	—	—	—
Other	5	—	—	—
	17	231	148	242

	2023	2024	2025	Q'26
Payables	7	10	21	29
ST’ Debt	—	—	—	—
Other	5	—	—	—
	16	18	29	37

Compound Annual Growth %

	10y	5y	3y
Sales	(15.22%)	(38.04%)	(56.57%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	28.86%	25.16%	55.90%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	0	0	—
’25	0	0	0	0	1
’24	0	0	0	1	1
’23	2	0	0	1	1
’22	3	3	3	3	11
’21	2	2	3	3	10
’20	2	2	3	2	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	(31)	(21)	—
’25	(16)	(25)	(22)	(20)	(82)
’24	3	(27)	14	(9)	(18)
’23	(2)	(9)	(10)	(8)	(37)
’22	(2)	(1)	(1)	(3)	(8)
’21	0	(1)	(2)	(1)	(3)
’20	(1)	(1)	(3)	(1)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	(38)	(35)	—
’25	(18)	(30)	(26)	(21)	(95)
’24	(26)	(41)	5	(10)	(72)
’23	(2)	(9)	(10)	(9)	(38)
’22	(2)	(1)	(1)	(3)	(8)
’21	0	(1)	(2)	(1)	(3)
’20	(1)	(1)	(3)	(1)	(4)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	(0.25)	(0.22)	—
’25	(0.35)	(0.51)	(0.25)	(0.29)	(1.40)
’24	(0.21)	(0.59)	(0.20)	(0.18)	(1.23)
’23	(0.30)	(0.96)	0.00	(0.40)	(1.70)
’22	(0.16)	(0.10)	(0.10)	(0.15)	(0.51)
’21	(0.10)	(0.10)	(0.06)	(0.01)	(0.33)
’20	(0.10)	(0.10)	(0.10)	(0.02)	(0.51)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.80	3.80	2.70	2.90	3.50	3.80	1.90	2.10	2.70	1.60	Analyst estimates 2026–2028 Powerpack
	High	13.00	6.90	12.20	7.80	10.60	28.10	4.50	7.30	19.10	5.39
People
People	Employees	41	36	38	43	53	61	66	119	140	166
	Revenue/emp, $m	0.12	0.13	0.16	0.17	0.18	0.16	0.16	0.01	0.01	0.01
Income, $m
Income, $m	Revenue	5	5	6	7	10	10	11	1	1	1
	Gross margin, %	2.70	17.60	31.10	41.66	52.93	50.94	42.76	100.00	100.00	100.00
	EBT	(5)	(6)	(7)	(5)	(3)	(3)	(7)	(40)	(80)	(104)
	EBT margin, %	(98.78)	(129.43)	(113.12)	(70.33)	(35.60)	(33.69)	(67.36)	(2,796.79)	(5,531.43)	(11,813.12)
	Net income	(5)	(6)	(7)	(5)	(3)	(3)	0	(47)	(79)	(103)
	Depreciation	0	0	0	0	0	0	0	1	26	1
Per share, $
Per share, $	Revenue	0.87	0.87	1.07	1.09	1.43	0.97	0.76	0.05	0.02	0.01
	Earnings	(0.86)	(1.12)	(1.21)	(0.77)	(0.51)	(0.33)	(0.51)	(1.70)	(1.23)	(1.40)
	Cash flow	(0.71)	(1.04)	(1.04)	(0.75)	(0.54)	(0.27)	(0.54)	(1.38)	(0.28)	(1.12)
	Capex	(0.09)	(0.10)	(0.06)	(0.06)	(0.04)	(0.04)	(0.02)	(0.04)	(0.84)	(0.17)
	Free cash flow	(0.79)	(1.14)	(1.10)	(0.81)	(0.58)	(0.31)	(0.56)	(1.42)	(1.12)	(1.29)
	Book value	2.98	1.93	0.91	1.15	0.85	6.49	0.00	2.81	4.51	2.80
	Shares, m	6	6	6	7	7	10	14	27	64	74
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	100.36	72.80	40.98	37.58	39.11	82.63	4.08	74.66	141.35	229.62
	P/B	29.18	32.69	48.25	35.79	66.15	12.32	0.72	1.42	0.71	0.98
	EV/Sales	98.24	71.55	40.40	36.85	38.94	76.34	(1.07)	69.38	(13.60)	67.67
	EV/FCF	(74.15)	(35.83)	(25.50)	(32.14)	(62.31)	(170.99)	1.45	(2.62)	0.27	(0.63)
Cash, $m
Cash, $m	Operating cash flow	(4)	(6)	(6)	(5)	(4)	(3)	(8)	(37)	(18)	(82)
	Capex	0	(1)	0	0	0	0	0	(1)	(54)	(13)
	Free cash flow	(4)	(6)	(6)	(5)	(4)	(3)	(8)	(38)	(72)	(95)
Balance, $m
Balance, $m	Working capital	13	9	4	6	4	66	50	1	213	120
	Total debt	—	—	—	—	1	1	0	2	2	2
	Net debt	(10)	(6)	(3)	(5)	(2)	(63)	(44)	(8)	(225)	(143)
	Shareholders’ equity	16	11	5	8	6	67	55	75	291	207
Returns, %
Returns, %	ROA	(22.98)	(40.65)	(68.05)	(61.09)	(38.15)	(8.57)	0.00	(59.63)	(36.12)	(33.92)
	ROIC	(50.72)	(84.41)	(262.03)	(139.50)	(52.99)	(52.50)	0.00	(37.84)	(86.89)	(111.14)
	ROE	(25.40)	(45.72)	(85.86)	(81.12)	(51.59)	(9.27)	0.00	(71.65)	(43.34)	(41.44)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%	Compare
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)	Compare
Median of peers	$263.2M	20.0×	—	+2.16%	—	−7.70%	70.04%	(90.09%)

All 149 Medical Devices stocks →

Perspective Therapeutics, Inc. (CATX) key facts

Concern: Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024.
Perspective Therapeutics, Inc. (CATX) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, CATX traded at $2.17, a market capitalization of $267.1 million.
Return on equity was −41.4% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.59 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.